Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Trop Doct ; 52(3): 456-458, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35321613

RESUMEN

A 50-year old diabetic male presented with cough, breathlessness, fever, and chest pain. Clinical and radiological evaluation revealed a right-sided pyopneumothorax. Surgical drainage with tube thoracostomy was performed. Pleural fluid cultures grew Enterococcus fecium as a sole organism. Our patient was treated with vancomycin and amikacin with an excellent clinical response. Enterococci are rarely implicated in the lower respiratory tract and pleural infections and are not usually considered if initiating empirical treatment. Their intrinsic resistance to empirically used antibiotics may complicate the course of the disease. Hence initial Gram staining and expeditious microbiological isolation with susceptibility testing is warranted in all cases. Gram-positive aerobes, notably staphylococcus followed by streptococcus and pneumococcus, are the commonly encountered organisms in pleural infections.


Asunto(s)
Empiema Pleural , Neumotórax , Antibacterianos/uso terapéutico , Empiema Pleural/diagnóstico , Empiema Pleural/tratamiento farmacológico , Empiema Pleural/etiología , Humanos , Masculino , Persona de Mediana Edad , Neumotórax/diagnóstico , Neumotórax/etiología , Staphylococcus
2.
J Clin Diagn Res ; 10(8): OC06-10, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27656477

RESUMEN

INTRODUCTION: Even though the links between upper and lower airway had been of interest to clinicians since long back, it has not attracted the attention of the researchers till recent past. But the evidence is still far from conclusive, due to limited number of randomized controlled trials available on subjects with concomitant allergic rhinitis and asthma. This gap in the knowledge is even more conspicuous in Indian population. AIM: The current study is conducted with an objective of comparing the efficacy and tolerability of intranasal Fluticasone and oral Montelukast in treatment of allergic rhinitis and bronchial asthma. MATERIALS AND METHODS: The study was a prospective randomized, single blinded, comparative, parallel group study, with two intervention groups conducted in a tertiary teaching hospital in Chennai, Southern India. One hundred and twenty patients diagnosed with concomitant diagnosis of allergic rhinitis and bronchial asthma was randomly allocated to either Fluticasone propionate aqueous nasal spray or oral Montelukast group. RESULTS: Out of total 120 subjects recruited, 108 subjects were included in the final analysis. The mean reduction in asthma and rhinitis symptom scores and improvement in PEFR was higher for Group A, compared to Group B during all the follow-up periods. No statistically significant difference was observed in proportion of subjects reporting exacerbations in the current study. Both the treatments were well tolerated. CONCLUSION: Addition of intranasal Fluticasone propionate to Salmeterol plus Fluticasone is beneficial in improving asthma control, allergic rhinitis control and lung functions as compared to oral Montelukast. Thereby the use of intranasal Fluticasone Propionate in comparison to oral Montelukast in control of Allergic Rhinitis is justified as per the significant improvement in outcome measures.

3.
J Clin Diagn Res ; 10(4): OD03-5, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27190865

RESUMEN

A phyllodes tumour is a malignancy of both mesenchymal and epithelial origin affecting the breast. The malignant course of this breast tumour causing lung metastasis is rare. Here we report a treated case of borderline phyllodes tumour that presented with pleuroparenchymal metastasis. Our case highlights the possibility of recurrence of borderline phyllodes tumour as pleuroparenchymal metastasis even after a long disease free interval.

4.
Mol Immunol ; 68(2 Pt A): 325-32, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26455524

RESUMEN

Mycobacterium tuberculosis has evolved to employ multiple strategies to avoid an efficient host immune response. Accordingly, enzymes are important antimycobacterial elements and apoptosis decides the fate of any cell. Hence, we carried out this study to discern the amplitude of two clinical stains (S7 & S10) and a laboratory strain (H37Rv) of M. tuberculosis in modifying the release of lytic enzymes and apoptosis of neutrophils from healthy volunteers and pulmonary tuberculosis patients. We detected reduced levels of elastase in neutrophils from pulmonary tuberculosis patients. The laboratory strain H37Rv is found to increase the release of elastase and myeloperoxidase in neutrophils from both the groups. This strain is more efficient compared to clinical strains in inducing late apoptosis/necrosis in neutrophils. Our results proclaim the susceptibility of neutrophils in responding to infection with H37Rv. Also, at the functional level, neutrophils undergo changes related to release of enzymes after acquiring tuberculosis.


Asunto(s)
Elastasa de Leucocito/metabolismo , Mycobacterium tuberculosis/inmunología , Neutrófilos/enzimología , Superóxido Dismutasa/metabolismo , Tuberculosis Pulmonar/enzimología , Adulto , Apoptosis , Estudios de Casos y Controles , Femenino , Interacciones Huésped-Patógeno , Humanos , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/crecimiento & desarrollo , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/microbiología , Cultivo Primario de Células , Acetato de Tetradecanoilforbol/farmacología , Tuberculosis Pulmonar/inmunología , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/patología
5.
Int J Mycobacteriol ; 4(4): 312-7, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26964814

RESUMEN

There is an urgent need for a rapid and reliable test to detect actively multiplying Mycobacterium tuberculosis directly from clinical specimens for an early initiation of the appropriate antituberculous treatment. This study was aimed at the optimization and application of nested reverse transcriptase-PCR (nRT-PCR) targeting the messenger RNA of the icl2, hspx, and rRNAP1 genes directly from sputum specimens, and their evaluation against the culture by the BACTEC MicroMGIT mycobacterial culture system. 203 Sputum samples from clinically suspected tuberculosis patients and 30 control specimens (clinically proven viral or bacterial infections other than tuberculosis) were included in this study. The mycobacterial culture was performed by the BACTEC MicroMGIT system following the manufacturer's instructions. The primers for nRT-PCRs targeting icl2, hspx, and rRNAP1 genes were indigenously designed using the Primer-BLAST software, and optimized for sensitivity and specificity. The icl2, hspx, and rRNAP1 genes were able to pick up 63.9%, 67.2%, and 58.75%, respectively, of culture-negative sputum specimens collected from clinically suspected tuberculosis patients. However, three (1.4%) were negative for nRT-PCR, but M. tuberculosis culture positive. All the 30 controls were negative for culture by the BACTEC MicroMGIT method and all three nRT-PCR. The novel nRT-PCRs targeting icl2, hspx, and rRNAP1 genes developed in this study are rapid and reliable diagnostic tools to detect viable M. tuberculosis directly from sputum specimens. However, further study by including a larger number of sputum specimens needs to be carried out to ascertain the diagnostic utility of the novel nRT-PCRs optimized in the study.


Asunto(s)
Antígenos Bacterianos/genética , Proteínas Bacterianas/genética , Mycobacterium tuberculosis/aislamiento & purificación , Reacción en Cadena de la Polimerasa/métodos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Tuberculosis Pulmonar/microbiología , Humanos , Mycobacterium tuberculosis/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Esputo/microbiología , Tuberculosis Pulmonar/diagnóstico
6.
Genome Announc ; 2(6)2014 Nov 13.
Artículo en Inglés | MEDLINE | ID: mdl-25395642

RESUMEN

We announce the draft genome sequence of two extensively drug-resistant Mycobacterium tuberculosis strains, VRFCWCF XDRTB 232 and VRFCWCF XDRTB 1028, isolated from the sputum samples of a patient clinically suspected to have tuberculosis, and we also report novel mutations that confer drug resistance.

7.
Clin Infect Dis ; 59(10): e142-9, 2014 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-25028463

RESUMEN

BACKGROUND: Rapid sputum culture conversion at 2 months indicates the sterilizing capacity and potential of regimens to shorten duration of tuberculosis treatment. We compared results of sputum culture conversion by moxifloxacin and control regimens and identified factors affecting sputum culture positivity after 2 months of treatment. METHODS: Human immunodeficiency virus-uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- or 4-month moxifloxacin regimen (moxifloxacin [M], isoniazid [H], rifampicin [R], pyrazinamide [Z], ethambutol [E]) or the control regimen (RHZE thrice weekly). Bacteriological assessments were done at 15, 30, 45, and 60 days of treatment. Because all patients in the moxifloxacin groups received 2 months of daily RHZEM, they were grouped together for analysis. Statistical methods included χ(2) test and logistic regression analysis. RESULTS: Sputum culture conversion was analyzed in 780 (616 in the moxifloxacin group and 164 in the control group) of 801 enrolled patients. Ninety-five percent of 590 patients in the moxifloxacin group and 81% of 151 patients in the control group had negative sputum cultures at month 2 (P < .001). The control regimen, age (≥35 years), initial sputum culture grade (2+ or 3+), and male sex were significantly associated with higher odds of positive sputum cultures at 2 months. CONCLUSIONS: A 5-drug daily regimen with moxifloxacin results in significantly higher sputum culture conversion in the first 2 months compared with a thrice-weekly, 4-drug regimen in patients with newly diagnosed sputum-positive pulmonary tuberculosis.


Asunto(s)
Antituberculosos/uso terapéutico , Fluoroquinolonas/uso terapéutico , Esputo/microbiología , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/tratamiento farmacológico , Adulto , Antituberculosos/administración & dosificación , Antituberculosos/efectos adversos , Esquema de Medicación , Farmacorresistencia Bacteriana , Quimioterapia Combinada , Femenino , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/efectos adversos , Estudios de Seguimiento , Humanos , India , Masculino , Persona de Mediana Edad , Moxifloxacino , Radiografía Torácica , Sistema de Registros , Factores de Riesgo , Resultado del Tratamiento , Adulto Joven
8.
Hum Immunol ; 75(8): 914-22, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24994463

RESUMEN

Neutrophils being innate cells initiate the immune defence against mycobacteria by sending signals to other immune cells. Chemokines being the vital link in signaling processes, it is of interest to study their secretion by neutrophils as a response to tuberculosis infection. The levels of various chemokines (MIP-1α, MCP-1, IL-8 and IP-10) and chemokine receptors (CXCR1, CXCR2 and CCR1) in neutrophils from healthy individuals and pulmonary tuberculosis patients were studied following infection with Mycobacterium tuberculosis strains (clinical--S7 and S10 and laboratory--H37Rv). The release of MIP-1α, IL-8 and MCP-1 is found to be greatly increased in patient neutrophils. Mycobacterial strains differentially influenced neutrophils affecting the release of chemokines to different extent. H37Rv significantly increased the release of MIP-1α and IL-8 in both normals and tuberculosis patients, while S10 up regulated only the release of MIP-1α in patients. Thus, during tuberculosis, neutrophils undergo functional alteration to combat infection. While H37Rv is greatly recognized by neutrophils and triggers the release of chemokines, clinical strains by some means try to suppress immune activation of neutrophils in their favor.


Asunto(s)
Quimiocina CCL2/inmunología , Quimiocina CCL3/inmunología , Interleucina-8/inmunología , Mycobacterium tuberculosis/inmunología , Neutrófilos/inmunología , Tuberculosis Pulmonar/inmunología , Adulto , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Quimiocina CCL3/genética , Quimiocina CCL3/metabolismo , Femenino , Regulación de la Expresión Génica , Interacciones Huésped-Patógeno , Humanos , Interleucina-8/genética , Interleucina-8/metabolismo , Masculino , Persona de Mediana Edad , Neutrófilos/microbiología , Neutrófilos/patología , Cultivo Primario de Células , Receptores CCR1/genética , Receptores CCR1/inmunología , Receptores de Interleucina-8A/genética , Receptores de Interleucina-8A/inmunología , Receptores de Interleucina-8B/genética , Receptores de Interleucina-8B/inmunología , Transducción de Señal , Tuberculosis Pulmonar/genética , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...